Filter
251
Text search:
FDC
Featured
Recommendations
39
New Publications
88
Language
Document type
No document type
188
Guidelines
26
Studies & Reports
20
Training Material
6
Manuals
4
Fact sheets
4
Situation Updates
1
Resource Platforms
1
Strategic & Response Plan
1
Countries / Regions
India
18
Tanzania
12
South Africa
11
Kenya
10
Namibia
10
Malawi
8
Ghana
5
Uganda
5
Zambia
5
Indonesia
5
Bangladesh
5
Burkina Faso
4
Nigeria
4
Ethiopia
4
Zimbabwe
4
Nepal
4
Cambodia
4
Global
4
Philippines
3
Sierra Leone
2
Mozambique
2
Eswatini/ Swaziland
2
Botswana
2
Myanmar / Burma
2
Latin America and the Carribbean
2
Liberia
1
Senegal
1
Congo, Democratic Republic of
1
Cameroon
1
Pakistan
1
Afghanistan
1
Gambia
1
Rwanda
1
Madagascar
1
Lesotho
1
Sri Lanka
1
South–East Asia Region
1
Western and Central Europe
1
Bhutan
1
Albania
1
Timor Leste/ East Timor
1
Tajikistan
1
Gabon
1
France
1
Authors & Publishers
Publication Years
Category
Countries
129
Clinical Guidelines
39
Public Health
6
Pharmacy & Technologies
6
Capacity Building
3
Key Resources
2
Toolboxes
TB
63
HIV
43
AMR
14
Pharmacy
8
NTDs
3
NCDs
3
Polio
2
Refugee
2
Specific Hazards
1
Global Health Education
1
COVID-19
1
Malaria
1
MSF International AIDS Working Group
- A Skills Building Program for Clinicians and Non-Clinicians. Adherence guidelines- slide deck- training course for health providers
Vinay P. Saldanha( UNAIDS Regional Director- Eastern Europe & Central Asia)
Session 1 Wednesday 30/01/2019
30-31 January 2019, Bucharest
Accessed: 29.09.2019
The new, all oral, 20-month MDR-TB regimens range from US $1,600* (using bedaquiline and linezolid for 6 months and levofloxacin as the fluoroquinolone) to US $2,100* (using linezolid for 12 months and moxifloxacin as the fluoroquinolone.
This resource consists of technical guidelines for District Medical Officers, counselors and laboratory technicians for second-line antiretroviral therapy drugs, operational guidelines for pilot roll-out in two centres and laboratory guidelines for viral-load testing and standard operating procedure
...
The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evidence-based policies.
Vol. 2: Clinicians' Guide
Clinicians’ Guide is designed to assist busy medical practitioners in the field with patient management by providing current, essential, practical guidance and background, packaged into a single resource
Clinicians’ Guide is designed to assist busy medical practitioners in the field with patient management by providing current, essential, practical guidance and background, packaged into a single resource
Guidelines for treatment of drug-susceptible tuberculosis and patient care
Update 2017
NOVEMBER 2012
This document serves as an update to “Out of the Dark”, a report published by MSF in October 2011, highlighting the need to prioritise the long-neglected area of paediatric tuberculosis (TB). This update will outline the key improvements and setbacks—the ‘highlights’ and ‘
...
NATIONAL TUBERCULOSIS AND LEPROSY PROGRAMME
Tuberculosis (TB) is among the top ten most common causes of death globally and as a single infectious disease it top among infectious diseases. Furthermore, it is noted as the top causes of death among people infected with the human immunodeficiency virus (HIV). Despite recent decreases in the numb
...
